Recent discussions on X about Humacyte, Inc. (HUMA) have been buzzing with interest following Barclays' initiation of coverage with an Overweight rating and a price target of $3.50. Many users are captivated by the potential of Humacyte's vascular device technology, with some highlighting the significant market opportunity estimated at over $600 million. The stock's recent volatility has also sparked debates about its near-term trajectory.
Posts on X reflect a mix of optimism and curiosity, with several focusing on the innovative bioengineered tissue solutions and past FDA approvals as key drivers of future growth. There's also chatter about strategic developments and analyst predictions, keeping the conversation dynamic. As the company continues to navigate market challenges, the dialogue remains fixated on whether these projections will materialize.
Note: This discussion summary was generated from an AI condensation of post data.
Humacyte, Inc. Insider Trading Activity
Humacyte, Inc. insiders have traded $HUMA stock on the open market 12 times in the past 6 months. Of those trades, 6 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $HUMA stock by insiders over the last 6 months:
- BRADY W DOUGAN has made 0 purchases and 3 sales selling 2,241,045 shares for an estimated $3,733,191.
- LAURA E NIKLASON (President, CEO and Director) has made 0 purchases and 3 sales selling 2,241,045 shares for an estimated $3,733,191.
- KATHLEEN SEBELIUS purchased 50,000 shares for an estimated $66,000
- DALE A. SANDER (CFO and Chief Corp. Deve. Off.) purchased 20,000 shares for an estimated $30,600
- MICHAEL T. CONSTANTINO purchased 16,000 shares for an estimated $20,160
- SHAMIK J PARIKH (Chief Medical Officer) purchased 7,500 shares for an estimated $11,625
- WILLIAM JOHN SCHEESSELE (Chief Commercial Officer) purchased 6,493 shares for an estimated $9,999
- CHARLES BRUCE GREEN purchased 6,000 shares for an estimated $7,740
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Humacyte, Inc. Hedge Fund Activity
We have seen 106 institutional investors add shares of Humacyte, Inc. stock to their portfolio, and 87 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEIGHTS CAPITAL MANAGEMENT, INC removed 4,025,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $8,412,250
- RA CAPITAL MANAGEMENT, L.P. removed 3,312,356 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,922,824
- MARSHALL WACE, LLP added 2,590,394 shares (+5308.2%) to their portfolio in Q2 2025, for an estimated $5,413,923
- CITADEL ADVISORS LLC removed 2,287,143 shares (-78.5%) from their portfolio in Q2 2025, for an estimated $4,780,128
- TORONTO DOMINION BANK removed 2,131,390 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,454,605
- CENTERBOOK PARTNERS LP added 2,007,743 shares (+141.1%) to their portfolio in Q2 2025, for an estimated $4,196,182
- MONASHEE INVESTMENT MANAGEMENT LLC removed 2,000,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,179,999
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Humacyte, Inc. Analyst Ratings
Wall Street analysts have issued reports on $HUMA in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 08/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/12/2025
- D. Boral Capital issued a "Buy" rating on 08/11/2025
- Benchmark issued a "Buy" rating on 05/14/2025
To track analyst ratings and price targets for Humacyte, Inc., check out Quiver Quantitative's $HUMA forecast page.
Humacyte, Inc. Price Targets
Multiple analysts have issued price targets for $HUMA recently. We have seen 6 analysts offer price targets for $HUMA in the last 6 months, with a median target of $8.75.
Here are some recent targets:
- Matt Miksic from Barclays set a target price of $3.5 on 08/27/2025
- Joshua Jennings from TD Cowen set a target price of $3.5 on 08/12/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $3.0 on 08/12/2025
- Jason Kolbert from D. Boral Capital set a target price of $25.0 on 08/11/2025
- Bruce Jackson from Benchmark set a target price of $14.0 on 05/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
